Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Mark Eisner sold 6,796 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total value of $37,174.12. Following the transaction, the executive vice president directly owned 108,204 shares in the company, valued at $591,875.88. This trade represents a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Mark Eisner also recently made the following trade(s):

• On Thursday, July 17th, Mark Eisner sold 3,586 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.47, for a total transaction of $19,615.42.

Vir Biotechnology Stock Up 1.5%

Shares of NASDAQ:VIR traded up $0.08 during trading on Thursday, hitting $5.49. 1,282,059 shares of the company were exchanged, compared to its average volume of 1,369,327. The business's 50 day moving average is $5.13 and its 200-day moving average is $6.97. The company has a market capitalization of $758.94 million, a P/E ratio of -1.30 and a beta of 1.22. Vir Biotechnology, Inc. has a 1-year low of $4.32 and a 1-year high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative return on equity of 47.46% and a negative net margin of 2,769.04%. The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $8.59 million. During the same period in the prior year, the business earned ($0.48) EPS. The company's revenue for the quarter was down 94.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Hedge Funds Weigh In On Vir Biotechnology

Large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vir Biotechnology in the 4th quarter worth $42,000. GAMMA Investing LLC lifted its stake in shares of Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock valued at $46,000 after acquiring an additional 5,972 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after acquiring an additional 1,999 shares in the last quarter. FORA Capital LLC purchased a new stake in shares of Vir Biotechnology in the 1st quarter worth approximately $70,000. Finally, Syon Capital LLC purchased a new stake in shares of Vir Biotechnology during the fourth quarter valued at approximately $77,000. Institutional investors own 65.32% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on VIR. Raymond James Financial began coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They set an "outperform" rating on the stock. The Goldman Sachs Group lowered their price target on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Finally, Needham & Company LLC reissued a "buy" rating and set a $14.00 price objective on shares of Vir Biotechnology in a report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Vir Biotechnology currently has a consensus rating of "Moderate Buy" and an average price target of $30.25.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.